| 引用本文: | 王丽满,徐丹,魏晓霞,黄旭慧.非布司他治疗维持性腹膜透析伴痛风患者的疗效及安全性观察[J].中国现代应用药学,2020,37(23):2888-2892. |
| WANG Liman,XU Dan,WEI Xiaoxia,HUANG Xuhui.Efficacy and Safety Observation of Febuxostat in the Treatment of Maintenance Peritoneal Dialysis Patients Complicated with Gout[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(23):2888-2892. |
|
| 本文已被：浏览 5221次 下载 2465次 |
码上扫一扫！ |
|
|
| 非布司他治疗维持性腹膜透析伴痛风患者的疗效及安全性观察 |
|
王丽满1,2, 徐丹1,2, 魏晓霞3, 黄旭慧1,2
|
|
1.福建省立医院南院/福建省立金山医院药学部, 福州 350028;2.福建医科大学省立临床医学院, 福州 350001;3.福建省立医院药学部, 福州 350001
|
|
| 摘要: |
| 目的 探讨非布司他在维持性腹膜透析合并痛风患者中的临床疗效及安全性。方法 选取福建省立金山医院肾内科2016年5月—2019年5月收治的46例维持性腹膜透析伴痛风患者，按治疗方法的不同分为2组，对照组接受别嘌醇治疗，观察组接受非布司他治疗，均随访6个月。比较2组患者治疗期间血尿酸、肝功能及肌钙蛋白I的变化，同时记录2组患者治疗期间的不良反应以及痛风再发作次数。结果 治疗后，2组患者血尿酸均降低，且观察组的血尿酸水平显著低于对照组（P<0.05），观察组总有效率高于对照组（P<0.05）。2组患者肝功能、心血管事件比较无显著差异，但降尿酸治疗初期，观察组的痛风发作次数高于对照组（P<0.05）。结论 非布司他较别嘌醇更能有效地降低维持性腹膜透析伴痛风患者的血尿酸，且无明显不良反应，有一定的临床推广应用价值。 |
| 关键词: 非布司他 别嘌醇 痛风 维持性腹膜透析 疗效 安全性 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.23.013 |
| 分类号:R969.4 |
| 基金项目:福建医科大学启航基金项目（2017XQ1133）；福建省卫生计生青年科研课题（2016-1-33） |
|
| Efficacy and Safety Observation of Febuxostat in the Treatment of Maintenance Peritoneal Dialysis Patients Complicated with Gout |
|
WANG Liman1,2, XU Dan1,2, WEI Xiaoxia3, HUANG Xuhui1,2
|
|
1.Department of Pharmacy, Fujian Provincial Hospital South Branch/Fujian Provincial Hospital Jinshan Branch, Fuzhou 350028, China;2.Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China;3.Department of Pharmacy, Fujian Provincial Hospital, Fuzhou 350001, China
|
| Abstract: |
| OBJECTIVE To explore the curative effect and safety of febuxostat in the treatment of maintenance peritoneal dialysis patients complicated with gout. METHODS Forty-six maintenance peritoneal dialysis patients complicated with gout were enrolled in Fujian Provincial Hospital Jinshan Branch from May 2016 to May 2019. All the patients were divided into the experimental group treated with febuxostat and the control group treated with allopurinol for 6 months. The serum uric acid, liver function, cardiac troponin I as well as the incidence of adverse reactions and the number of recurrence of gout were observed and compared between two groups in the treatment period. RESULTS The levels of serum uric acid in two groups were decreased after treatment, moreover, the concentration of serum uric acid in the experimental group were significantly lower than those in the control group(P<0.05). In addition the effective rates of the experimental group were higher than those in the control group(P<0.05). There was no significant difference in liver function and cardiovascular events among the two groups. However, the number of acute gout attack in the experimental group was higher than that in the control group in the early stage of uric lowering therapy(P<0.05). CONCLUSION Compared with allopurinol, febuxostat has better clinical effect in treatment of patients undergoing maintenance peritoneal dialysis complicated with gout, which can obviously reduce the levels of serum uric acid with little adverse reactions and may have a certain clinical application value. |
| Key words: febuxostat allopurinol gout maintenance peritoneal dialysis curative effect safety |
